BTG3 and synovial sarcoma: Up to 85% of patients have ANA, anti‐Ro/SSA and anti‐La/SSB antibodies, which appear in 33%–74% and 23%–52% of SS patients, respectively, are regarded as crucial immunological indicators of the disease [194].